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A B S T R A C T
Purpose
Survival after metastatic cancer has improved at the cost of increased presentation with metastatic
spinal disease. For patients with pathologic spinal fractures and/or spinal cord compression, surgical
intervention may relieve pain and improve quality of life. Surgery is generally considered to be
inappropriate if anticipated survival is , 3 months. The aim of this international multicenter study
was to analyze data from patients who died within 3 months or 2 years after surgery, to identify
preoperative factors associated with poor or good survival, and to avoid inappropriate selection of
patients for surgery in the future.
Patients and Methods
A total of 1,266 patients underwent surgery for impending pathologic fractures and/or neuro-
logic deﬁcits and were prospectively observed. Data collected included tumor characteristics,
preoperative ﬁtness (American Society of Anesthesiologists advisory [ASA]), neurologic status
(Frankel scale), performance (Karnofsky performance score [KPS]), and quality of life (EuroQol
ﬁve-dimensions questionnaire [EQ-5D]). Outcomes were survival at 3 months and 2 years
postsurgery. Univariable and multivariable logistic regression analyses were used to ﬁnd pre-
operative factors associated with short-term and long-term survival.
Results
In univariable analysis, age, emergency surgery, KPS, EQ-5D, ASA, Frankel, and Tokuhashi/Tomita
scores were signiﬁcantly associated with short survival. In multivariable analysis, KPS and age were
signiﬁcantly associatedwith short survival (odds ratio [OR], 1.36; 95%CI, 1.15 to 1.62; and OR, 1.14;
95% CI, 1.02 to 1.27, respectively). Associated with longer survival in univariable analysis were
age, number of levels included in surgery, KPS, EQ-5D, Frankel, and Tokuhashi/Tomita scores. In
multivariable analysis, the number of levels included in surgery (OR, 1.21; 95% CI, 1.06 to 1.38) and
primary tumor type were signiﬁcantly associated with longer survival.
Conclusion
Poor performance status at presentation is the strongest indicator of poor short-term survival,
whereas low disease load and favorable tumor histology are associated with longer-term
survival.
J Clin Oncol 34:3054-3061. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Because of improvements in systemic therapy,
survival of patients with metastasized cancer has
improved substantially in the past decade.1 As
a result, the number of patients with symptomatic
spinal metastases is increasing, which necessitates
the development of new strategies to improve
the quality of the remaining lifespan for individ-
ual patients.2 Currently, painful spinal metastases
without signs of gross mechanical instability or
spinal cord compression can usually be treated
successfully with external beam irradiation.3 With
increasing mechanical instability or in the pres-
ence of pathologic fractures and/or symptomatic
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spinal cord compression, surgical intervention may be warranted
to provide mechanical stability and/or to decompress neural
structures.4
In general, spine surgeons select less-demanding in-
terventions for patients with limited life expectancy and
save larger interventions for patients with relatively good
prognosis.5,6 After the introduction of less-invasive techniques,
minimum life expectancy required for patients to beneﬁt from
surgery has decreased as time to recovery and surgical de-
mand is reduced.7 Now, spine surgeons may perform palliative
surgery with the goal of increasing quality of life, provided
the patient has a reasonable chance to survive for at least
3 months.8 Patients with life expectancies , 3 months are
generally regarded as unsuitable for surgery as the risks and
drawbacks, including pre- and postoperative complications,
managing postoperative pain, and time required for recovery,
are considered to outweigh the beneﬁts of intervention, and
patients are subsequently referred for radiotherapy or palliative
medical care.5,8,9 Similarly, patients who undergo highly de-
manding surgery need a sufﬁciently large life expectancy to
recover and to beneﬁt from these larger procedures. Because of
a lack of solid selection criteria, surgeons currently rely mainly
on subjective clinical and radiologic assessments to determine
the extent of surgery deemed appropriate. The number of
patients who do not receive optimal surgical care as a result of
under- or overtreatment is not known; therefore, it would be
valuable to identify preoperative factors associated with ex-
ceedingly short survival to learn which patients may not ben-
eﬁt from surgery and to also identify factors associated with
prolonged survival to help select patients who will potentially
beneﬁt from larger interventions. The aim of this study was
to review those patients who underwent spinal surgery for
symptomatic spinal metastases, but who died within 3 months
of surgery, and contrast this with long-term survivors (. 2 years).
Patients who died within 3 months of surgery might be con-
sidered as having received surgery inappropriately and, there-
fore, we set out to identify preoperative factors which might
indicate that anticipated survival does not justify the risk
of surgery.
PATIENTS AND METHODS
For this prospective, observational, longitudinal cohort study, patients
with surgically treated symptomatic spinal metastases were consecutively
included in 23 internationally recognized spine centers. Indications for
surgery were back pain caused by mechanical instability and/or neurologic
symptoms as assessed by the treating spine surgeon and according to
institutional practices and guidelines.10 All principal investigators adhered
to the principle that to perform any type of spine surgery, life expectancy
for individual patients should be no less than 3 months as established by
the treating oncologist. Participating centers were located in Belgium,
Canada, People’s Republic of China, Denmark, France, Germany, Japan,
the Netherlands, Spain, South Korea, the United Kingdom, and the United
States. All centers collected predeﬁned parameters prospectively and en-
tered anonymized data via a secure internet database.10,11 Institutional
review board approval was obtained for all centers following local regu-
lations. Data collection started in March 2001 and continued until October
2014 when the database was closed for data analysis to answer our speciﬁc
research questions. Anonymous case records were kept for individual
patients and included detailed information on primary tumor histology,
oncologic treatment received previously, preoperative characteristics, and
surgical, discharge, and follow-up data. Although patients with multiple
myeloma can be regarded as a distinct category, they were included because
of similarity in management. Patients were observed from enrollment up
to 2 years after surgery or death. Table 1 gives a detailed listing of collected
parameters. Primary outcome was survival at 3 months postsurgery and
secondary outcome was survival at 2 years postsurgery. To ensure reliability
of primary and secondary outcomes, participating investigators reviewed
all their case records after closure of the database with special emphasis on
vital statistics—being dead or alive—for each patient.
Table 1. Parameters Scored and Their Deﬁnitions
Parameter Deﬁnition
Age at surgery Years
Gender Male and female
Surgical priority Emergency (, 1 day), urgent
(1-3 days), scheduled (. 3 days)
Spinal levels affected No. of levels
Karnofsky performance score Scale of 0-100
EQ-5D index EuroQol ﬁve-dimensions
questionnaire
Frankel category Frankel grading system (A/B/C/D/E)
Tokuhashi score 0-15 points
Tomita score 2-10 points
Paralysis = yes Wheelchair bound or conﬁned to bed
ASA score American Society for
Anesthesiologists score (1-4)
Histologic tumor diagnosis Breast, colorectal, renal, lung,
prostate, myeloma, gastric, liver,
bladder, lymphoma, melanoma,
sarcoma, thyroid, miscellaneous
No. of extraspinal metastasis
locations
0-4
Preoperative pain level Numeric rating scale (0-10)
Intraoperative complications Vascular; neurologic; visceral
Postoperative complications,
including directly related to surgical
intervention
Hematoma, infection, implant failure,
CSF leakage, wound breakdown,
neurologic deterioration, other
Cause of death Related to disease, unrelated to
disease, related to spine treatment,
related to spine surgery, other/not
known
Included in the 3-month
 analysis                              (n = 1,060) 
Excluded, not confirmed
 alive at 3 months                 (n = 206) 
Included in the 24-month
 analysis                                    (n = 839)
Excluded, alive but did not yet
 reach 24 months follow-up      (n = 98)
Excluded, not confirmed
 alive at 24 months                  (n = 329) 
Two-year analysis
Died within 2 years         (n = 618) 
Alive at least 2 years     (n = 221)
Three-month analysis
Died within 3 months      (n = 173) 
Alive at least 3 months   (n = 887) 
Patients enrolled in the Global
Spine Tumour Study Group
(N = 1,266)
Fig 1. CONSORT diagram.
www.jco.org © 2016 by American Society of Clinical Oncology 3055
Characteristics of Patients Who Survived < 3 Months
Downloaded from ascopubs.org by Cruciform Library - Cruciform Building on January 16, 2017 from 193.062.074.026
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Statistical Analysis
Data distributions were reviewed before analysis of results and cal-
culations of statistical parameters. Univariable and multivariable logistic
regression analyses of cases without missing data were performed to
assess factors associated with dying within 3 months after surgery and
factors associated with survival after surgery for . 2 years. Pertinent
variables—considered directly relevant to the outcome but not obviously
interrelated or similar to other variables—were included in multivariable
analysis if observed at least 400 times. Sensitivity analyses were per-
formed to test the inﬂuence of missing values on results. P values , .05
were considered signiﬁcant. All statistical tests were performed with Stata
13.1 software (STATA, College Station, TX; Computing Resource Center,
Santa Monica, CA).
RESULTS
A total of 1,266 patients were included in the database. The cohort
used in the analysis is under ongoing follow-up. Of 1,266 patients,
1,060 patients have been observed past 3 months or have died
within this period; 839 have been observed past 2 years or have died
Table 2. Baseline Characteristics for All Patients
Characteristic Observed No. Overall (N = 1,266) Alive (n = 648) Died (n = 618)
Age at surgery, mean (SD), years 1,266 60.7 (12.3) 59.6 (12.5) 61.8 (11.9)
Male, No. (%) 1,261 715 (56.5) 349 (53.9) 366 (59.2)
First surgery type, No. (%) 941
Emergency 163 (17.3) 76 (14.2) 87 (21.4)
Scheduled 484 (51.4) 297 (55.6) 187 (46.0)
Urgent 294 (31.2) 161 (30.2) 133 (32.7)
Spinal levels affected, median (IQR) 1,266 1 (1-3) 1 (1-3) 2 (1-3)
Preoperative KPS score, mean (SD) 1,000 60.2 (20.5) 65.0 (20.5) 55.6 (19.4)
Preoperative EQ-5D, median (IQR) 902 0.38 (0.16-0.69) 0.44 (0.20-0.71) 0.31 (0.12-0.60)
Preoperative Frankel category, No. (%) 1,239
A/B/C 314 (25.3) 128 (20.0) 186 (31.0)
D 432 (34.9) 217 (33.9) 215 (35.8)
E 494 (39.8) 295 (46.1) 199 (33.2)
Tokuhashi score, No. (%) 877
0-8 380 (43.0) 166 (33.2) 214 (55.9)
9-11 351 (39.8) 219 (43.8) 132 (34.5)
12-15 152 (17.3) 115 (23.0) 37 (9.7)
Tomita score, No. (%) 1,110
# 3 373 (33.6) 260 (44.1) 113 (21.7)
4/5 249 (22.4) 144 (24.4) 105 (20.1)
6/7 252 (22.7) 119 (20.2) 133 (25.5)
$ 8 238 (21.4) 67 (11.4) 171 (32.8)
Paralysis, yes, No. (%) 1,266 352 (27.8) 143 (22.1) 209 (33.8)
ASA, No. (%) 1,031
1 123 (11.9) 91 (15.9) 32 (7.0)
2 457 (44.3) 275 (48.0) 182 (39.7)
3 403 (39.1) 195 (34.0) 208 (45.4)
4 48 (4.7) 12 (2.1) 36 (7.9)
Metastatic tumor diagnosis, No. (%)
Breast 234 (18.5) 148 (22.8) 86 (13.9)
Colorectal 54 (4.3) 15 (2.3) 39 (6.3)
Renal 163 (12.9) 88 (13.6) 75 (12.1)
Lung (any) 163 (12.9) 67 (10.3) 96 (15.5)
Prostate 168 (13.3) 67 (10.3) 101 (16.3)
Myeloma 85 (6.7) 66 (10.2) 19 (3.1)
Gastric 18 (1.4) 3 (0.5) 15 (2.4)
Liver 21 (1.7) 9 (1.4) 12 (1.9)
Bladder 15 (1.2) 3 (0.5) 12 (1.9)
Lymphoma 21 (1.7) 17 (2.6) 4 (0.7)
Melanoma 27 (2.1) 15 (2.3) 12 (1.9)
Sarcoma 18 (1.4) 7 (1.1) 11 (1.8)
Thyroid 37 (2.9) 24 (3.7) 13 (2.1)
Other speciﬁed 59 (4.7) 25 (3.9) 34 (5.5)
Other unknown 183 (14.5) 94 (14.5) 89 (14.4)
Metastasis locations, No. (%) 1,266
0 891 (70.4) 495 (76.4) 396 (64.1)
1 228 (18.0) 109 (16.8) 119 (19.3)
2 102 (8.1) 31 (4.8) 71 (11.5)
3 39 (3.1) 12 (1.9) 27 (4.4)
4 6 (0.5) 1 (0.2) 5 (0.8)
Abbreviations: ASA, American Society of Anesthesiologists; EQ-5D, EuroQol ﬁve-dimensions questionnaire; IQR, interquartile range; KPS, Karnofsky performance
score; SD, standard deviation.
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in this period (Fig 1). Univariable and multivariable regression
analyses are exclusively run on these two, smaller groups. Average
age of the patients at time of surgery was 60.7 6 12.3 years and
56.5% of the population was male. Surgical interventions were
performed on a scheduled basis in 51.4% and urgent or emergency
basis in 48.6% of patients. The ﬁve most frequent histologic tumor
types were (in order): cancer of the breast, unknown primary,
prostate, kidney, and lung. Mean preoperative Karnofsky perfor-
mance score (KPS) was 60.26 20.5. Neurologic status was normal
(Frankel E) in 39.8%, mildly impaired (Frankel D) in 34.9%, and
grossly impaired (Frankel C/B/A) in 25.3% of patients. Median
number of spinal levels that warranted surgical intervention was
one. The majority of surgical procedures (84.4%) were performed
intralesionally, which reﬂected the predominantly palliative
character of the intervention. Table 2 gives a detailed listing of
baseline characteristics of all patients.
Patients Who Survived < 3 Months
Descriptive analysis of the group of survivors at 3 months
versus those who had died at that point showed that patients who
had died within 3 months were in a signiﬁcantly worse condition
preoperatively with more emergency cases, lower preoperative
KPS, lower preoperative EQ-5D, more severe neurologic deﬁcits,
worse Tokuhashi and Tomita categorical scores, worse ASA scores,
and more often presented with unfavorable tumor histology and
extraspinal and visceral metastases. Table 3 displays detailed de-
scriptive analysis of the two groups of patients at 3 months
postsurgery.
Comparison of characteristics from patients who had a
follow-up visit at, at least, 3 months or were discharged at this
point (n = 887) with those who had died by 3 months (n = 173)
demonstrated the following factors associated with dying within
3 months in univariable analysis: age per 5-year increase (odds
ratio [OR], 1.12; 95% CI, 1.04 to 1.20; P = .001), emergency
surgery (OR, 2.06; 95% CI, 1.34 to 3.17; P = .002), preopera-
tive KPS per 10-unit decrease (OR, 1.51; 95% CI, 1.36 to 1.67;
P, .001), preoperative EQ-5D per unit decrease (OR, 7.47; 95%CI,
3.77 to 14.79; P , .001), and preoperative ASA, Frankel, and
Tokuhashi and Tomita categorical scores. Table 4 gives a detailed
overview of these factors. In multivariable analysis, however,
preoperative KPS per 10-unit decrease and age were the only
signiﬁcant factors associated with dying within 3 months (OR,
1.36; 95% CI, 1.15 to 1.62; P , .001; and OR, 1.14; 95% CI, 1.02
to 1.27; P = .02, respectively). Appendix Figure A1 (online only)
presents a graphical representation of 3-month survival stratiﬁed
by preoperative KPS. Causes of death for the 173 patients who
died within 3 months were systemic progression of cancer (n = 146;
84.4%), a result of complications of spine surgery within 30 days
of surgery (n = 7; 4.0%), and not known or not speciﬁed (n = 20;
11.6%).
Patients Who Survived > 2 Years
Descriptive analysis for patients who survived . 2 years
postsurgery compared with those who had died by 2 years after
surgery showed survivors to have a favorable preoperative con-
dition with lower age, better preoperative KPS and EQ-5D scores,
less (and less severe) neurologic deﬁcits, better ASA, Frankel, and
Tokuhashi and Tomita categorical scores, more favorable tumor
histology, and less extraspinal and visceral metastases (Table 5).
Comparison of patients who survived for at least 2 years
(n = 221) with patients who died within 2 years after surgery
Table 3. Descriptive Analysis of Survivors Versus Nonsurvivors at 3 Months
Variable
Alive
(n = 887)
Died
(n = 173) P
Age at surgery, mean (SD),
years
60.0 (12.3) 63.3 (11.3) .001
Male, No. (%) 491 (55.4) 116 (67.1) .004
First surgery type, No. (%) , .001
Emergency 109 (17.2) 38 (29.9)
Scheduled 349 (55.0) 47 (37.0)
Urgent 177 (27.9) 42 (33.1)
Preoperative KPS, mean (SD) 62.3 (20.4) 47.6 (16.9) ,.001
Preoperative EQ-5D, median
(IQR)
0.44 (0.20-0.70) 0.18 (0.06-0.44) .001
Preoperative Frankel
category, No. (%)
, .001
A/B/C 188 (21.6) 72 (42.9)
D 301 (34.6) 60 (35.7)
E 381 (43.8) 36 (21.4)
Tokuhashi score, No. (%) , .001
0-8 232 (39.3) 82 (66.1)
9-11 241 (40.8) 38 (30.7)
12-15 118 (20.0) 4 (3.2)
Tomita score, No. (%) , .001
# 3 291 (36.6) 21 (15.0)
4/5 183 (23.0) 19 (13.6)
6/7 169 (21.3) 41 (29.3)
$ 8 152 (19.1) 59 (42.1)
Paralysis, yes, No. (%) 217 (24.5) 85 (49.1) , .001
ASA, No. (%) .007
1 91 (12.6) 7 (5.4)
2 305 (42.3) 48 (37.2)
3 293 (40.6) 62 (48.1)
4 32 (4.4) 12 (9.3)
Intraoperative complications,
yes, No. (%)
63 (7.1) 11 (6.4) .73
Surgical complications, yes,
No. (%)
149 (19.2) 49 (30.6) .001
Metastatic tumor diagnosis,
No. (%)
, .001
Breast 183 (20.6) 14 (8.1)
Colorectal 37 (4.2) 11 (6.4)
Renal 115 (13.0) 18 (10.4)
Lung (any) 108 (12.2) 31 (17.9)
Prostate 114 (12.9) 35 (20.2)
Myeloma 59 (6.7) 7 (4.1)
Gastric 14 (1.6) 4 (2.3)
Liver 14 (1.6) 3 (1.7)
Bladder 6 (0.7) 7 (4.1)
Lymphoma 13 (1.5) 1 (0.6)
Melanoma 19 (2.1) 2 (1.2)
Sarcoma 15 (1.7) 2 (1.2)
Thyroid 27 (3.0) 3 (1.7)
Other speciﬁed 40 (4.5) 6 (3.5)
Other unknown 123 (13.9) 29 (16.8)
Metastasis locations, No. (%) , .001
0 641 (72.3) 92 (53.2)
1 157 (17.7) 38 (22.0)
2 64 (7.2) 28 (16.2)
3 23 (2.6) 12 (6.9)
4 2 (0.2) 3 (1.7)
Complications, yes, No. (%) 254 (28.6) 67 (38.7) , .001
Abbreviations: ASA, American Society of Anesthesiologists; EQ-5D, EuroQol
ﬁve-dimensions questionnaire; IQR, interquartile range; KPS, Karnofsky per-
formance score; SD, standard deviation.
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(n = 618) demonstrated in univariable analysis the following
factors associated with dying within 2 years after surgery: age per
5-year increase (OR, 1.14; 95% CI, 1.07 to 1.22; P , .001),
number of affected spinal levels included in surgery per addi-
tional level (OR, 1.09; 95% CI, 1.02 to 1.17; P = .007), pre-
operative KPS per 10-unit decrease (OR, 1.26; 95% CI, 1.15 to
1.37; P = .04), preoperative EQ-5D per unit decrease (OR, 3.74;
95% CI, 2.05 to 6.80; P , .001), and preoperative Frankel and
Tokuhashi and Tomita categorical scores. Table 6 gives a detailed
overview of these factors. In multivariable analysis, the number
of affected spinal levels included in surgery (per additional level:
OR, 1.21; 95%CI, 1.06 to 1.38; P, .005) and primary tumor type
were signiﬁcant factors associated with dying in 2 years. Of all
patients with one affected spinal level included in surgery, 34.9%
were alive at 2 years after surgery, whereas of all patients with two or
more affected spinal levels included in surgery, 22.7% were alive at
that point. Sensitivity analyses performed for both short- and long-
term survival cohorts did not show any change in the signiﬁcance
of the results (Appendix Tables A1 and A2, online only).
DISCUSSION
In this study, preoperative factors associated with short- and long-
term survival were investigated in a prospectively observed cohort
of 1,266 patients who underwent surgery for treatment of
symptomatic spinal metastases. Our results suggest that patients
dying within 3 months after surgery were in a signiﬁcantly worse
physical condition preoperatively than were those who survived
beyond the ﬁrst 3 months, independent of unfavorable primary
tumors or visceral metastases. Second, longer-term survivors were
in a relatively good condition preoperatively and required surgery
for only a limited number of spinal metastases, and their survival
was associated with more favorable primary tumor types. Expe-
rienced clinicians may have an intuitive feel for when a patient is
not a suitable candidate for surgery. Our results suggest that this
intuition has a scientiﬁc basis, as the main predictor of short-term
survival is functional status. KPS has previously also been shown to
be a predictor of quality of life for patients who were surgically
treated for spinal metastases and may therefore become a pre-
dominant prognostic variable for decision making.6
Spinal metastases are common ($ 70%) in patients with end-
stage cancer.12 Approximately 5% to 10% of patients with spinal
metastases require surgical intervention as a result of mechanically
unstable painful lesions and/or impending neurologic deﬁcits.13
Clinical outcome of patients who require surgical treatment of
spinal metastases depends predominantly on appropriate patient
selection. This process is complex and involves the synthesis of
several factors, many of which are uncertain, unreliable, or
unreproducible, to determine the risk:beneﬁt ratio of surgery.
Calculation of the risk:beneﬁt ratio is dependent upon the accuracy
with which the factors involved can be determined. Unfortunately,
many preoperative factors that are thought to be relevant for
clinical outcome are not only difﬁcult to quantify but also often
interdependent (performance, for example, depends on the
presence of neurologic deﬁcits and/or pain) or are not yet known.
As a result, some patients may not receive operative treatment,
although they could have beneﬁtted from it, whereas others
Table 4. Logistic Regression Analysis Exploring Factors Associated With Dying Within 3 Months After Surgery
Variable No.
Unadjusted Analysis Multivariable Analysis
Odds Ratio (95% CI) P Odds Ratio (95% CI) P
Age at surgery (per 5-year increase) 1,060 1.12 (1.04 to 1.20) .001 1.14 (1.02 to 1.27) .02
First surgery type (odds for emergency) 762 2.06 (1.34 to 3.17) .002 1.20 (0.67 to 2.15) .54
Spinal levels affected (per additional level) 1,060 1.05 (0.99 to 1.11) .11 1.04 (0.97 to 1.13) .27
Preoperative KPS (per 10-unit decrease) 843 1.51 (1.36 to 1.67) , .001 1.36 (1.15 to 1.62) , .001
Preoperative EQ-5D (per unit decrease) 730 7.47 (3.77 to 14.79) , .001 — —
Preoperative Frankel category 1,038 , .001 .41
E Ref Ref
D 2.11 (1.36 to 3.28) 1.53 (0.78 to 3.00)
A/B/C 4.05 (2.62 to 6.27) 1.55 (0.73 to 3.27)
Tokuhashi category (surgery) 715 , .001 — —
12-15 Ref
9-11 4.65 (1.62 to 13.34)
0-8 10.43 (3.73 to 29.14)
Tomita category (surgery) 935 , .001 — —
# 3 Ref
4/5 1.44 (0.75 to 2.75)
6/7 3.36 (1.92 to 5.88)
$ 8 5.38 (3.15 to 9.19)
Paralysis (odds for paralysis) 1,060 2.98 (2.13 to 4.17) , .001 — —
ASA 850 .007 — .77
1 Ref Ref
2 2.05 (0.89 to 4.68) 1.06 (0.42 to 2.68)
3 2.75 (1.22 to 6.22) 1.10 (0.43 to 2.81)
4 4.88 (1.77 to 13.46) 1.93 (0.48 to 7.82)
Complications (odds for complications) 1,060 1.58 (1.12 to 2.21) .009 1.33 (0.79 to 2.23) .28
Abbreviations: ASA, American Society of Anesthesiologists; EQ-5D, EuroQol ﬁve-dimensions questionnaire; KPS, Karnofsky performance score; Ref, reference.
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undergo surgery only to succumb quickly because of rapid pro-
gression of disease. To help predict survival and guide treatment in
patients with metastatic spinal disease, various scoring systems
have been developed.14-18 Some of these systems were designed for
speciﬁc histologic tumor types, whereas others rely on general
biologic tumor behavior or extent of metastatic spread to predict
outcome. These scoring systems, however, do not provide in-
formation for two key questions that arise frequently in clinical
practice and are strongly related with short- and long-term
survival. First, will a speciﬁc patient beneﬁt from surgical in-
tervention or will surgery lead to accelerated systemic progression
of the malignant disease and subsequent death within 3 months?
Second, should the surgical procedure for this speciﬁc patient be
performed with longer-term survival in mind? For example, does
the patient need to achieve bony fusion of the instrumented spine
segments?
With regard to deciding whether to operate for spinal
metastases, several studies have shown that physicians are not
consistent when given the task of estimating the life expectancy
of a patient and often overestimate survival of patients with
cancer.19 This overestimation may lead to the decision to
perform surgery on patients who will not live long enough to
beneﬁt from the procedure. More so, the surgical procedure
itself may negatively inﬂuence survival in patients with cancer
to the extent that the expected remaining lifespan that was
assumed preoperatively is shortened. Evidence is emerging that
mechanisms of perioperative immunosuppression as a result of
factors that include, but are not limited to, surgical stress and
injury, anesthetic agents, and blood transfusions may impair
immunosurveillance and lead to inﬂammatory reactions that
might promote metastatic growth.20 Results of our study show
that the majority of patients who died within 3 months (146 of
173; 84.4%) succumbed because of rapid progression of the
malignant process, rather than surgical complications. This
suggests that survival may have been inﬂuenced, in part, by
systemic effects of the surgical procedure and the balance
between the malignant process and tumor control by immu-
nosurveillance.20 This balance may be more delicate and easily
tipped in patients with poor preoperative physical condi-
tion, as our results clearly show worse survival for patients with
unfavorable preoperative parameters, including KPS, ASA, and
neurologic status. In addition, it is possible that patients
who are referred by oncologists for palliative spinal surgery
and are estimated to have a remaining life span of approx-
imately # 6 months will not have many chemotherapeutic
options remaining to counter accelerated systemic progression
of disease.
As patients undergo surgery for spinal metastases are treated
in a palliative setting to improve quality of life, minimizing surgical
insult is imperative. The extent and execution of the index surgery,
however, should be sufﬁcient to function as intended for the
remaining life of the patient, thus avoiding any revision or repeat
surgeries. For patients with longer life expectancy, performing
more demanding index surgery may be preferable over less de-
manding, lower risk operations that may not be long-lasting and
carry a higher risk of repeat surgery. The promising results of
immunotherapy for tumors that were previously considered to be
therapy resistant may lead to a change from tumor histology to
biologic tumor behavior after treatment as the important prog-
nostic factor for long-term survival after surgical treatment of
spinal metastases.21
Table 5. Descriptive Analysis of Survivors Versus Nonsurvivors at 2 Years
Variable Alive (n = 221) Died (n = 618) P
Age at surgery, years,
mean (SD)
57.6 (12.9) 61.8 (11.9) , .001
Male, No. (%) 119 (53.9) 366 (59.2) .17
First surgery type, No. (%) .001
Emergency 27 (14.4) 87 (21.4)
Scheduled 118 (62.8) 187 (46.0)
Urgent 43 (22.9) 133 (32.7)
Spinal levels affected, median
(IQR)
1 (1-3) 2 (1-3) .14
Preoperative KPS, mean (SD) 64.9 (21.1) 55.6 (19.4) , .001
Preoperative EQ-5D, median
(IQR)
0.46 (0.26-0.77) 0.31 (0.12-0.60) .001
Preoperative Frankel
category, No. (%)
, .001
A/B/C 36 (16.4) 186 (31.0)
D 72 (32.7) 215 (35.8)
E 112 (50.9) 199 (33.2)
Tokuhashi score, No. (%) , .001
0-8 50 (27.6) 214 (55.9)
9-11 86 (47.5) 132 (34.5)
12-15 45 (24.9) 37 (9.7)
Tomita score, No. (%) , .001
# 3 99 (50.0) 113 (21.7)
4/5 44 (22.2) 105 (20.1)
6/7 36 (18.2) 133 (25.5)
$ 8 19 (9.6) 171 (32.8)
Paralysis, yes, No. (%) 52 (23.5) 209 (33.8) .005
ASA, No. (%) , .001
1 32 (16.5) 32 (7.0)
2 92 (47.4) 182 (39.7)
3 68 (35.1) 208 (45.4)
4 2 (1.0) 36 (7.9)
Intraoperative complications,
yes, No. (%)
12 (5.4) 37 (6.0) .76
Surgical complications, yes,
No. (%)
49 (22.2) 131 (21.2) .76
Metastatic tumor diagnosis,
No. (%)
, .001
Breast 56 (25.3) 86 (13.9)
Colorectal 2 (0.9) 39 (6.3)
Renal 28 (12.7) 75 (12.1)
Lung (any) 19 (8.6) 96 (15.5)
Prostate 27 (12.2) 101 (16.3)
Myeloma 29 (13.1) 19 (3.1)
Gastric 1 (0.5) 15 (2.4)
Liver 2 (0.9) 12 (1.9)
Bladder 0 (0.0) 12 (1.9)
Lymphoma 5 (2.3) 4 (0.6)
Melanoma 6 (2.7) 12 (1.9)
Sarcoma 4 (1.8) 11 (1.8)
Thyroid 4 (1.8) 13 (2.1)
Other speciﬁed 1 (0.5) 34 (5.5)
Other unknown 37 (16.7) 89 (14.4)
Metastasis locations, No. (%) .006
0 164 (72.2) 396 (64.1)
1 42 (19.0) 119 (19.3)
2 10 (4.5) 71 (11.5)
3 5 (2.3) 27 (4.4)
4 0 5 (0.8)
Complications, yes, No. (%) 55 (24.9) 202 (32.7) .031
Abbreviations: ASA, American Society of Anesthesiologists; EQ-5D, EuroQol
ﬁve-dimensions questionnaire; IQR, interquartile range; KPS, Karnofsky per-
formance score; SD, standard deviation.
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The current study shows better survival for patients who
undergo surgery when still in reasonably good physical shape.
Because most surgical procedures for patients with spinal me-
tastases need to be performed in specialized centers, appro-
priate and timely referral is of paramount importance for good
clinical outcome.22 As a general rule, patients with a malig-
nancy in the medical history who develop back and neck pain
and/or neurologic deﬁcits have symptomatic spinal metastases
until proven otherwise and require immediate work-up, in-
cluding appropriate imaging of the entire spinal column. The
recently developed Spinal Instability Neoplastic Score is
a useful instrument to help to determine which patients should
then be referred to a spine surgery service.23,24
Although our current study showed consistency over
multiple preoperative domains of improved survival for ﬁtter
patients, several biases may be present. First, although each
participating center provided up-to-date information on vital
statistics, inaccuracies pertaining to the actual status of the
patient—being dead or alive—cannot be ruled out as many
patients were referred back to their own referring hospital or
home physicians. As the chance of the patient being registered
as alive in the database but being dead in reality is much higher
than the opposite; this potential inaccuracy could have led to an
overestimation of effect of the end points. Second, as baseline
characteristics show, the cohort of patients was heterogeneous,
with a wide range in age, tumor histology, and neurologic status
at admission. The common factor for all patients was the need
for surgical treatment of symptomatic spinal metastases. For
each patient, indication to proceed with surgery was based on
the need to decompress neural structures and/or ﬁxate unstable
spinal segments, together with sufﬁcient ﬁtness to endure the
procedure (as assessed preoperatively by the anesthesiologist
and surgeon), and a presumed life expectancy of . 3 months
(as assessed by the referring oncologist).8 All these factors can
be biased by the experience and preference of the anesthesi-
ologist, surgeon, and oncologist, institutional preference, and
patient wishes. Finally, during multivariable analysis, only two
factors, KPS and age, were shown to be signiﬁcantly and in-
dependently associated with short-term survival, and two
factors, number of affected spinal segments involved in the
surgical procedure and primary tumor type, were predominant
for longer-term survival. Because the results from the uni-
variable analysis yielded many highly signiﬁcant factors, the
low number of signiﬁcant factors in the multivariable analysis
suggests a high level of interdependence of preoperative var-
iables. For example, factors such as Frankel score and paralysis
would overlap. We suggest that the plethora of signiﬁcant
factors in the univariable analysis, which all point in the same
direction, indicate that fairly strong conclusions can be drawn
from our work for the factors associated with survival in both
the short term and long term.
In conclusion, results from this large prospective cohort
study strongly suggest that survival depends on general pre-
operative ﬁtness for palliative surgery of symptomatic spinal
metastases. In particular, a low preoperative KPS is signiﬁcantly
and independently associated with poor short-term survival
(, 3 months), and a limited number of spinal metastases in-
volved in the surgical procedure and favorable primary tumor
type are signiﬁcantly and independently associated with longer-
term survival.
Table 6. Logistic Regression Analysis Exploring Factors Associated With Dying in 2 Years After Surgery
Variable No.
Unadjusted Analysis Multivariable Analysis
Odds Ratio (95% CI) P Odds Ratio (95% CI) P
Age at surgery (per 5-year increase) 839 1.14 (1.07 to 1.22) , .001 1.01 (0.99 to 1.23) .07
First surgery type (odds for emergency) 595 1.62 (1.01 to 2.60) .04 0.66 (0.35 to 1.27) .22
Spinal levels affected (per additional level) 839 1.09 (1.02 to 1.17) .007 1.21 (1.06 to 1.38) .005
Preoperative KPS (per 10-unit decrease) 676 1.26 (1.15 to 1.37) .04 1.13 (0.97 to 1.31) .12
Preoperative EQ-5D (per unit decrease) 576 3.74 (2.05 to 6.80) , .001 — —
Preoperative Frankel category 820 , .001 .27
E Ref Ref
D 1.68 (1.18 to 2.40) 1.38 (0.78 to 2.47)
A/B/C 2.91 (1.90 to 4.45) 1.93 (0.86 to 4.30)
Tokuhashi category (surgery) 564 , .001 — —
12-15 Ref
9-11 1.87 (1.12 to 3.12)
0-8 5.21 (3.06 to 8.87)
Tomita category (surgery) 720 , .001 — —
# 3 Ref
4/5 2.09 (1.34 to 3.26)
6/7 3.24 (2.05 to 5.11)
$ 8 7.88 (4.57 to 13.6)
Paralysis (odds for paralysis) 839 1.66 (1.17 to 2.36) .004 — —
ASA 652 , .001 — .76
1 Ref Ref
2 1.98 (1.14 to 3.43) 1.22 (0.58 to 2.57)
3 3.06 (1.74 to 5.36) 1.03 (0.46 to 2.28)
4 18 (3.99 to 81.14) 1 (—)
Complications (odds for complications) 839 1.47 (1.03 to 2.08) .03 1.22 (0.70 to 2.13) .48
Abbreviations: ASA, American Society of Anesthesiologists; EQ-5D, EuroQol ﬁve-dimensions questionnaire; KPS, Karnofsky performance score; Ref, reference.
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Fig A1. Relation between preoperative Karnofsky performance score and poor
survival.
Table A1. Sensitivity Analysis of Multivariable Logistic Regression Model of Table 4
Variable
Missing Patients Coded as Having Died Missing Patients Coded as Being Alive
Odds Ratio (95% CI) P Odds Ratio (95% CI) P
Age at surgery (per 5-year increase) 1.13 (1.04 to 1.22) .002 1.11 (1.00 to 1.23) .05
First surgery type (odds for emergency) 0.84 (0.53 to 1.32) .44 1.30 (0.74 to 2.30) .36
Spinal levels affected (per additional level) 1.01 (0.94 to 1.08) .89 1.05 (0.97 to 1.14) .19
Preoperative KPS (per 10-unit decrease) 1.13 (1.01 to 1.26) .04 1.37 (1.16 to 1.61) , .001
Preoperative Frankel category .04 .65
E Ref Ref
D 1.56 (0.99 to 2.56) 1.35 (0.70 to 2.62)
A/B/C 1.96 (1.14 to 3.37) 1.33 (0.64 to 2.76)
ASA .51 .65
1 Ref Ref
2 1.13 (0.63 to 2.03) 1.09 (0.44 to 2.75)
3 0.85 (0.46 to 1.59) 1.21 (0.48 to 3.07)
4 1.27 (0.43 to 3.72) 2.17 (0.57 to 8.29)
Complications (odds for complications) 1.00 (0.68 to 1.45) .98 1.41 (0.85 to 2.33) .18
Abbreviations: ASA, American Society of Anesthesiologists; KPS, Karnofsky performance score; Ref, reference.
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Table A2. Sensitivity Analysis of Multivariable Logistic Regression Model of Table 6
Variable
Missing Patients Coded as Having Died Missing Patients Coded as Being Alive
Odds Ratio (95% CI) P Odds Ratio (95% CI) P
Age at surgery (per 5-year increase) 1.08 (0.99 to 1.18) .08 1.04 (0.96 to 1.12) .32
First surgery type (odds for emergency) 0.84 (0.49 to 1.46) .54 0.70 (0.45 to 1.11) .13
Spinal levels affected (per additional level) 1.13 (1.01 to 1.27) .03 1.18 (1.08 to 1.30) , .001
Preoperative KPS (per 10-unit decrease) 1.07 (1.01 to 1.83) .05 1.12 (1.00 to 1.25) .06
Preoperative Frankel category .35 .84
E Ref Ref
D 1.22 (0.73 to 2.03) 1.06 (0.68 to 1.65)
A/B/C 1.68 (0.83 to 3.37) 1.18 (0.68 to 2.04)
ASA .71 .46
1 Ref Ref
2 0.85 (0.46 to 1.58) 1.25 (0.71 to 2.19)
3 0.75 (0.38 to 1.49) 1.37 (0.75 to 2.48)
4 1 (—) 2.61 (0.76 to 8.94)
Complications (odds for complications) 1.12 (0.70 to 1.80) .64 1.29 (0.88 to 1.89) .19
Abbreviations: ASA, American Society of Anesthesiologists; KPS, Karnofsky performance score; Ref, reference.
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